Current and Future Therapies for Hepatitis C Virus Infection

Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD 20892-1800,USA.
New England Journal of Medicine (Impact Factor: 55.87). 05/2013; 368(20):1907-17. DOI: 10.1056/NEJMra1213651
Source: PubMed
33 Reads
  • Source
    • "One of the most relevant biotechnological applications of these new semisynthetic lipases was in the regioselective deprotection of per-Oacetylated carbohydrates and nucleosides (Romero et al., 2012) (Fig. 2). Carbohydrates and nucleosides analogues have attracted intense interest in medicine, where they are used as antitumor and antiviral agents (Calvaresia and Hergenrother, 2013; Liang and Ghany, 2013). Several nucleoside analog reverse-transcriptase inhibitors have been licensed and used in treatment of HIV/AIDS, for example Zidovudine (Esté and Cihlar, 2010). "
    [Show abstract] [Hide abstract]
    ABSTRACT: The development of new and successful biotransformation processes of key interest in medicinal and pharmaceutical chemistry involves creating new biocatalysts with improved or even new activities and selectivities. This review emphasizes the new emerging developed strategies to achieve this goal, site-selective chemical modification of enzymes using tailor-made peptides, specific insertion of metals or organometallic complexes into proteins producing bio-catalysts with multiple activities and computational design for creating evolved artificial enzymes with non-natural synthetic catalytic activities. Copyright © 2014. Published by Elsevier Inc.
    Biotechnology Advances 01/2015; 33(5). DOI:10.1016/j.biotechadv.2014.12.010 · 9.02 Impact Factor
  • Source
    • "DAAs have achieved high response rates with cure in late-stage clinical trials, but high costs will limit their broad access. In addition, certain patient groups (e.g., genotype 3, renal failure, hepatic decompensation, and liver transplantation) will need complementary approaches (Chung and Baumert, 2014; Liang and Ghany, 2013). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Fighting viral infections is hampered by the scarcity of viral targets and their variability, resulting in devel-opment of resistance. Viruses depend on cellular molecules—which are attractive alternative tar-gets—for their life cycle, provided that they are dispensable for normal cell functions. Using the model organism Drosophila melanogaster, we iden-tify the ribosomal protein RACK1 as a cellular factor required for infection by internal ribosome entry site (IRES)-containing viruses. We further show that RACK1 is an essential determinant for hepatitis C virus translation and infection, indicating that its function is conserved for distantly related human and fly viruses. Inhibition of RACK1 does not affect Drosophila or human cell viability and proliferation, and RACK1-silenced adult flies are viable, indicating that this protein is not essential for general transla-tion. Our findings demonstrate a specific function for RACK1 in selective mRNA translation and un-cover a target for the development of broad antiviral intervention. INTRODUCTION
    Cell 11/2014; 159(5):1086 - 1095. DOI:10.1016/j.cell.2014.10.041 · 32.24 Impact Factor
  • Source
    • "Hepatitis C is a single-stranded RNA virus belonging to the flaviridae virus family [37]. Most of the cell cycle of the HCV virus occurs in the cytoplasm and, in contrast to HBV, HCV cannot integrate the host genome. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Hepatocellular carcinoma is related to various etiologies including hepatitis B, hepatitis C, high alcohol intake, aflatoxin B1 and metabolic syndrom. Most of the time HCC developped on cirrhosis. Consequently, the mechanims of carcinogenesis of these different risk factors are difficult to separate from the events leading to cirrhosis. In contrast, aflatoxin B1 and hepatitis B have a clear direct oncogenic role through point mutations in the TP53 tumor supressor gene and insertionnal mutagenesis respectively. Finally, next-generation sequencing and transcriptome analysis will refine our knowledge of the relationship between etiology and the genetic events that draw the mutationnal landscape of hepatocellular carcinoma.
    Baillière&#x027 s Best Practice and Research in Clinical Gastroenterology 10/2014; 28(5). DOI:10.1016/j.bpg.2014.08.006 · 3.48 Impact Factor
Show more


33 Reads
Available from